Valuation: Ocular Therapeutix, Inc.

Market Cap 1.41B 1.26B 1.15B 1.05B 1.98B 133B 2.03B 13.83B 5.53B 70.67B 5.3B 5.19B 223B P/E 2026 *
-4.31x
P/E 2027 * -4.55x
Enterprise Value 987M 880M 804M 733M 1.38B 93.27B 1.42B 9.66B 3.86B 49.4B 3.7B 3.63B 156B EV / Sales 2026 *
18.7x
EV / Sales 2027 * 11.6x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-9.94%
1 week-12.04%
Current month-7.75%
1 month-11.31%
3 months-24.35%
6 months-33.78%
Current year-47.03%
1 week 6.41
Extreme 6.41
7.24
1 month 6
Extreme 6
7.75
Current year 6
Extreme 6
13.03
1 year 6
Extreme 6
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 14/04/2024
Director of Finance/CFO 50 19/01/2026
Chief Tech/Sci/R&D Officer - 27/09/2021
Director TitleAgeSince
Chairman 57 30/06/2019
Director/Board Member 78 04/11/2012
Director/Board Member 66 19/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
08/10/26 Sell

General Counsel

-11,984 0.0057%
02/10/26 Sell

Executive/Senior Manager

-9,990 0.0047%
02/10/26 Sell

Chief Technology Officer

-10,869 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
-9.94%-12.04%-40.52%+97.24% 1.57B
-3.76%-0.65%+47.41%+140.35% 1,263B
-1.45%-1.05%+46.41%+79.94% 665B
-2.24%-0.88%+32.97%+103.82% 521B
-1.06%-2.49%+47.76%+65.10% 387B
-2.27%+0.42%+74.12%+42.14% 371B
-0.10%+1.38%+32.03%+60.93% 310B
+0.13%+7.59%+12.79%+36.73% 293B
-3.80%-0.10%+43.90%+70.56% 259B
-3.96%+1.18%+36.70%+105.38% 216B
Average -2.85%+2.20%+33.36%+80.22% 428.7B
Weighted average by Cap. -2.33%+1.15%+43.58%+92.43%

Financials

2026 *2027 *
Net sales 52.84M 47.08M 43.06M 39.22M 73.93M 4.99B 75.92M 517M 207M 2.64B 198M 194M 8.34B 102M 90.93M 83.17M 75.75M 143M 9.64B 147M 999M 400M 5.11B 383M 375M 16.12B
Net income -334M -298M -272M -248M -468M -31.58B -480M -3.27B -1.31B -16.73B -1.25B -1.23B -52.78B -330M -294M -269M -245M -462M -31.22B -475M -3.24B -1.29B -16.53B -1.24B -1.21B -52.18B
Net Debt -425M -379M -346M -316M -595M -40.17B -611M -4.16B -1.66B -21.28B -1.6B -1.56B -67.14B -225M -200M -183M -167M -314M -21.24B -323M -2.2B -880M -11.25B -844M -825M -35.49B
Projected Income Statement - Annual - Ocular Therapeutix, Inc.
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
05/11/26 US$6.430 -9.94% 3,130,008
04/11/26 US$7.140 +4.69% 3,360,664
03/11/26 US$6.820 +1.34% 2,001,472
02/11/26 US$6.730 -3.44% 1,883,301
30/10/26 US$6.970 -4.65% 2,629,770
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ocular Therapeutix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.430USD
Average target price
25.45USD
Spread / Average Target
+295.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ocular Therapeutix, Inc.
  1. Stock Market
  2. Stocks
  3. OCUL Stock